News Release

July 28, 2025


JCR Pharmaceuticals Co., Ltd.

JCR Receives National Honor for Supporting Children with Complex Medical Needs

Hyogo, Japan – **July 28, 2025 –** JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") has been awarded the Medal with Dark Blue Ribbon, a Japanese government honor presented by the Emperor to individuals and organizations that have made exceptional contributions to the public good through private donations.

This is the second time JCR has received this recognition for its ongoing support of Momiji House, a short-stay medical facility in Tokyo that provides round-the-clock care for children with serious medical conditions. Operated by the National Center for Child Health and Development, Momiji House offers children and their families a safe, home-like environment where they can rest and reconnect—often during difficult, hospital-centered lives.

Our donations have supported improvements to the facility's safety and accessibility, including the expansion of outdoor infrastructure for use in emergencies. On July 25, Dr. Jun Kitazawa, Director of the National Center, formally presented the commendation to JCR.



From the left: Jun Kitazawa, M.D., Director of the National Center for Child Health and Development and Toru Ashida, Director and Senior Managing Executive Officer of JCR

"Thank you very much for your longstanding support of Momiji House**,** " said Dr. Jun Kitazawa, "We are truly grateful that we have been able to continue providing a place where children requiring medical care and their families can feel at ease. Our vision of creating a 'second home' for children with complex medical needs is gradually expanding, starting with Momiji House. We remain committed to supporting these children so that even with serious illness they can live with dignity."

"We are deeply honored to receive this recognition for the second time," also said Toru Ashida, Director and Senior Managing Executive Officer of JCR, "we are committed not only to developing treatments for rare diseases, but also to supporting families who live with these conditions every day. Facilities like Momiji House play a vital role in bridging medicine and compassion, and we hope to see more such efforts take root in our society."

JCR has been supporting Momiji House since its founding in 2014. That commitment continues to shape how JCR sees its mission—not just to treat rare diseases, but to ensure that no one is left behind, no matter how rare their condition may be.

About Children with Medical Complexity

These are children who, following long-term hospitalization in neonatal intensive care units (NICUs), continue to require daily medical care such as ventilator support, feeding tubes, suctioning, or other life-sustaining treatments at home.

About Momiji House

Momiji House, established in April 2016 on the grounds of the National Center for Child Health and Development in Setagaya, Tokyo, is Japan's first short-stay medical facility for children with complex medical needs. It provides 24-hour medical care for children who require ongoing support at home and offers them and their families a few days of rest in a safe, home-like environment. The facility serves around 700 users annually.



もみじの家

Reference: Website of "Momiji House", a medical short-term facility for children of the National Center for Child Health and Development
https://momiji.ncchd.go.jp/ (in Japanese)

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: https://jcrpharm.com/.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###